Economic impact of infections in patients with cancer

  • David J. Shulkin
  • Lawrence J. Anastasi
Part of the Cancer Treatment and Research book series (CTAR)


The cost of caring for patients with cancer has been reported to total over $100 billion dollars per year [1]. Patients who have cancer have high utilization rates of medical care and have more medical interventions than patients with non-cancer-related diagnoses [2]. One study, that examined the costs associated with the treatment of cancer found treatment costs to be $29,708 a year [3].


Clin Oncol Chronic Lymphocytic Leukemia Febrile Neutropenia Neutropenic Fever Critical Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Leake AR. The economic impact of cancer. Nurse Practioner Forum, No. 4 (December), 1995, pp. 207–214.Google Scholar
  2. 2.
    Munoz E, Chalfin D, Rosner F, et al. Hospital costs, cancer patients and medical diagnosis-related groups. Onclogy 1988;45:401–404.CrossRefGoogle Scholar
  3. 3.
    Bloom BS, Knorr, Evans AE. The epidemiology of disease expense. The costs of caring for children with cancer. JAMA 1985;253:2393–2397.PubMedCrossRefGoogle Scholar
  4. 4.
    Haley RW, Schaberg DR. Extra charges and prolongation of stay attributable to nosocomial infections: A prospective interhospital compatison. Am J Med 1981;70:51–57.PubMedCrossRefGoogle Scholar
  5. 5.
    Shulkin DJ, Kinosian B, Glick H, Glen-Puschett C, Daly J, Eisenberg JM. The economic impact of infections. An analysis of hospital costs and charges in surgical patients with cancer. Arch Surg 1993:128:449–452.PubMedGoogle Scholar
  6. 6.
    Montero MC, Valdivia ML, Carvajal E, et al. Economic study of neutropenia induced by myelotoxic chemotherapy. Pharm World Sci 1994;16:187–192.PubMedCrossRefGoogle Scholar
  7. 7.
    DeVita, Hellman, Rosenburg (eds). Cancer: Principles and Practice of Oncology, 4th ed. 1993.Google Scholar
  8. 8.
    Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993;85:460–474.Google Scholar
  9. 9.
    Weeks JC, Tierney MR, Weinstein MC. Cost-effectiveness of prophylactic intravenous immune globulin in chronic lymphoctic leukemia. N Engl J Med 1991;325:81–86.PubMedCrossRefGoogle Scholar
  10. 10.
    Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic grwoth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85:488–493.PubMedCrossRefGoogle Scholar
  11. 11.
    Glaspy JA, Bleecker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stumulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993;29A(Suppl.):S23–S30.PubMedCrossRefGoogle Scholar
  12. 12.
    Riikonen P, Saarrian UM, Makipernaa A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: A double blind placebo-controlled study in children. J Pediatr Infect Dis 1994:13:197–202.CrossRefGoogle Scholar
  13. 13.
    Mayordomo JI, Rivera F, Diaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995;87:803–808.PubMedCrossRefGoogle Scholar
  14. 14.
    Lawless GD. Health resources utilization in ABMT with and without G-CSF in stage III/IV breast cancer patients. Oncology 1995(Suppl.):107–110.Google Scholar
  15. 15.
    Morstyn G, Foote M, Lieschke GJ. Hematopoietic growth factors in cancer chemotherpay. Cancer Chemother Biol Response Modif 1996;16:295–314.PubMedGoogle Scholar
  16. 16.
    Rosenshein MS, Farewell VT, Prire TH, et al. The cost effectiveness therapeutic and prophylactic leukocyte transfusions. N Engl J Med 1980;302:1058–1062.PubMedCrossRefGoogle Scholar
  17. 17.
    Guiguet M, Rekacewicz C, Leclerq B, et al. Effectiveness of simple measures to control an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections in an intensive care unit. Infect Control Hosp Epidemiol 1990;ll:23–26.CrossRefGoogle Scholar
  18. 18.
    Sawamura N, Akagi E, Narakoa I, Masunaga Y, Yokoyama S, Saijo N. Significance of the bioclean room during treatment of lung cancer. Jpn J Cancer Chemother 1984;11:253–259.Google Scholar
  19. 19.
    Ueda T, Shibata H, Nakamura H, et al. Efficacy of laminar air flow room with or without clean nursing for preventing infection in patients with acute leukemia. Jpn J Clin Oncol 1983;13(Suppl. 1):151–157.PubMedGoogle Scholar
  20. 20.
    Cimino MA, Rotstein CM, Moser JE. Assessment of cost-effective antibiotic therapy in the management of infections in cancer patients. Ann Pharmacother 1994;28:105–111.PubMedGoogle Scholar
  21. 21.
    Counsell R. Pratt J, Williams MV. Chemotherapy for germ cell tumors: Prophylactic ciprofloxacin reduces the incidence of neutropenic fever. Clin Oncol 1994;6:232–236.CrossRefGoogle Scholar
  22. 22.
    Velasco E. Costa MA, Martins CA, Nucci M. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. Am J Clin Oncol 1995;18:429–435.PubMedCrossRefGoogle Scholar
  23. 23.
    Rubinstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640–3646.CrossRefGoogle Scholar
  24. 24.
    Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995;172:1035–1041.PubMedGoogle Scholar
  25. 25.
    Shulin D. Critical pathways. In: Kelley. ed. Textbook of Internal Medicine, 3rd ed. Philadelphia: Lippincott-Raven, 1997, pp. 237–241.Google Scholar
  26. 26.
    Mullen CA, Buchanan GR. Early hospital discharge of children with cancer treated for fever and neutropenia: Identification and managment of the low-risk patient. J Clin Oncol 1990;8:1998–2004.PubMedGoogle Scholar
  27. 27.
    Tomiak A, Yau J, Huan S, et al. Duration of intravenous antibiotic and hospital stay for patients with febrile neutropenia after chemotherapy: Experience of Ottawa Regional Cancer Center. Proc Ann Mtg Am Soc Clin Oncol 1993;12:A1500.Google Scholar
  28. 28.
    El-Deiry W, Morris L. High cost of hospital admissions for cancer patients at low risk to develop complications from febrile neutropenia. Proc Ann Mtg Am Soc Clin Oncol 1993;12:A1606.Google Scholar
  29. 29.
    Bash RO, Katz JA, Cash JV, et al. Safety and cost-effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994;74:189–196.PubMedCrossRefGoogle Scholar
  30. 30.
    Mor V, Stalker MZ, Gralla R, et al. Day hospital as an alternative to inpatient care for cancer patients: A random assignment trial. J Clin Epidemiol 1988;41:771–785.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1998

Authors and Affiliations

  • David J. Shulkin
  • Lawrence J. Anastasi

There are no affiliations available

Personalised recommendations